基于治疗起始时间的晚期头颈部鳞状细胞癌癌症恶病质患病率及临床意义
本研究分析361例晚期头颈部鳞状细胞癌患者,按治疗后第一年随访时段统计癌症恶病质患病率:治疗前22例(6.1%)、治疗后即刻148例(41%)、治疗后6个月66例(18.4%)、治疗后12个月65例(18.7%)。6个月和12个月持续存在或新发恶病质与复发及非癌症健康事件(NCHE)显著相关(p < .05)。恶病质患者癌症特异性死亡、非癌症死亡及总死亡概率更高(p < .05)。
要点
- 治疗后即刻恶病质患病率最高,达41%(148/361)。
- 6个月和12个月持续或新发恶病质与复发及NCHE显著相关(p < .05)。
- 恶病质患者癌症特异性死亡、非癌症死亡及总死亡概率更高(p < .05)。
核心结论
- 治疗后6个月和12个月存在癌症恶病质提示复发、非癌症健康事件及死亡风险更高。
研究设计与样本
- 研究纳入361例接受根治性初始治疗的晚期头颈部鳞状细胞癌患者,按治疗后第一年随访时段分析癌症恶病质患病率。
- 同时按随访期间恶病质发生情况分析复发、非癌症健康事件及病因特异性生存结局。
主要发现
- 癌症恶病质在治疗前、治疗后即刻、治疗后6个月、治疗后12个月分别为22例(6.1%)、148例(41%)、66例(18.4%)、65例(18.7%),共361例患者。
- 治疗后6个月和12个月持续存在或新发恶病质与复发及NCHE发生显著相关(p < .05)。
- 病因特异性生存分析中,恶病质患者癌症特异性死亡、非癌症死亡及总死亡概率更高(p < .05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to identify the prevalence of cancer cachexia and its prognostic impact in patients with advanced head and neck squamous cell carcinoma (HNSCC). METHODS: The prevalence of cancer cachexia was analyzed according to the follow-up periods during the first year after curative initial treatment. Recurrences, noncancer health events (NCHEs), and cause-specific survival outcomes were also analyzed according to the incidence of cancer cachexia during follow-up. RESULTS: Cancer cachexia was identified in 22 (6.1%), 148 (41%), 66 (18.4%), and 65 (18.7%) of 361 enrolled patients at pretreatment, immediately after treatment, 6-months after treatment, and 12-months after treatment, respectively. Sustained or newly developed cachexia at 6 and 12 months showed a significant association with recurrence and NCHE occurrence (p < .05). In cause-specific survival analysis, patients with cachexia had a higher probability of cancer-specific death, noncancerous death, and overall death (p < .05). CONCLUSION: Cachexia prevalence at 6 and 12 months after treatment for HNSCC indicates a higher chance of recurrence, NCHE, and death. © 2016 Wiley Periodicals, Inc. Head Neck 39: 716-723, 2017.
引用
- Kwon M, Kim RB, Roh JL, et al. Prevalence and clinical significance of cancer cachexia based on time from treatment in advanced-stage head and neck squamous cell carcinoma. Head Neck. 2016. PMID: 28000343. doi:10.1002/hed.24672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。